The Antiviral Activity of a Small Molecule Drug Targeting the NSP1-Ribosome Complex Against Omicron, Especially in Elderly Patients

    March 2023 in “ Frontiers in Cellular and Infection Microbiology ”
    Min Shen, Ping Ding, Guangxin Luan … Shanshan Deng
    Studysummary This study found that Golvatinib, Gliquidone, and Dihydroergotamine may inhibit the binding of SARS-CoV-2's Nsp1 protein to the host ribosomal subunit, suggesting potential as treatments against COVID-19 variants.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 2

    1. Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19 Pharmacological Reports · 2020
    2. Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19 2020